CN101365477A - 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) - Google Patents

治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) Download PDF

Info

Publication number
CN101365477A
CN101365477A CNA2006800486507A CN200680048650A CN101365477A CN 101365477 A CN101365477 A CN 101365477A CN A2006800486507 A CNA2006800486507 A CN A2006800486507A CN 200680048650 A CN200680048650 A CN 200680048650A CN 101365477 A CN101365477 A CN 101365477A
Authority
CN
China
Prior art keywords
pro
arg
gly
peptide
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800486507A
Other languages
English (en)
Chinese (zh)
Inventor
P·佩特泽尔鲍尔
R·亨宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Publication of CN101365477A publication Critical patent/CN101365477A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800486507A 2005-12-23 2006-11-10 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) Pending CN101365477A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA2067/2005 2005-12-23
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen

Publications (1)

Publication Number Publication Date
CN101365477A true CN101365477A (zh) 2009-02-11

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800486507A Pending CN101365477A (zh) 2005-12-23 2006-11-10 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels)

Country Status (14)

Country Link
US (1) US7897574B2 (enExample)
EP (2) EP2110136A3 (enExample)
JP (1) JP2009520696A (enExample)
KR (1) KR20080108221A (enExample)
CN (1) CN101365477A (enExample)
AT (2) AT502987A1 (enExample)
AU (1) AU2006326890A1 (enExample)
CA (1) CA2634026A1 (enExample)
DE (1) DE502006004619D1 (enExample)
ES (1) ES2331970T3 (enExample)
IL (1) IL192349A0 (enExample)
NO (1) NO20083191L (enExample)
RU (1) RU2008130413A (enExample)
WO (1) WO2007070899A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1987062B1 (en) * 2006-02-23 2011-06-22 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
WO2009039542A2 (en) * 2007-09-24 2009-04-02 Fibrex Medical Research & Development Gmbh Methods of screening for compounds having anti- inflammatory activity and/or prevent / treat vascular leak
US20130324469A1 (en) * 2010-12-09 2013-12-05 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
US20170112941A1 (en) * 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患／急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) * 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
SI1341819T1 (sl) * 2000-12-12 2006-10-31 Fibrex Medical Res & Dev Gmbh Uporaba fibrinskih/fibrinogenskih peptidov in proteinov za pripravo zdravila
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
SI1691827T1 (sl) * 2004-06-25 2010-01-29 Fibrex Medical Res & Dev Gmbh Uporaba peptidov, izvedenih iz Bbeta-verige človeškega fibrinogena, za zdravljenje šoka
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock

Also Published As

Publication number Publication date
EP2110136A2 (de) 2009-10-21
JP2009520696A (ja) 2009-05-28
US20090005310A1 (en) 2009-01-01
EP2110136A3 (de) 2010-01-27
ES2331970T3 (es) 2010-01-21
AU2006326890A1 (en) 2007-06-28
RU2008130413A (ru) 2010-01-27
WO2007070899A3 (de) 2007-10-04
EP1962887A2 (de) 2008-09-03
CA2634026A1 (en) 2007-06-28
DE502006004619D1 (de) 2009-10-01
AT502987A1 (de) 2007-07-15
WO2007070899A2 (de) 2007-06-28
EP1962887B1 (de) 2009-08-19
KR20080108221A (ko) 2008-12-12
IL192349A0 (en) 2008-12-29
ATE440282T1 (de) 2009-09-15
US7897574B2 (en) 2011-03-01
NO20083191L (no) 2008-09-16

Similar Documents

Publication Publication Date Title
Ames et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.
Smith et al. How it all starts: Initiation of the clotting cascade
Malfait et al. Bleeding in the heritable connective tissue disorders: mechanisms, diagnosis and treatment
ES3055824T3 (en) Plasminogen replacement therapy for plasminogen-deficiency
DK2683397T3 (en) FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES
JP6404833B2 (ja) 止血組成物
Donahue et al. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass
EP1691827B1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
EP2996713A1 (en) Compositions and methods for treating post-operative complications of cardiopulmonary surgery
US7897574B2 (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
Hsu et al. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery
JP2017508806A (ja) 出血性疾患の治療における止血を改善するためのヒトプロトロンビン及び活性化第ｘ因子の組成物
TW200529870A (en) Therapeutic use of factor XI
JP5268638B2 (ja) 新規局所用抗出血剤としての活性型第Ｘ因子（ＦＸａ）の刺激因子
COHLER et al. Lung Vascular Injury with Protease Infusion Relationship to Plasma Fibronectin
MX2008008324A (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
Vu et al. A review of alkaline phosphatase in preventing systemic inflammation after cardiac surgery
US20030220253A1 (en) Inhibitors for use in hemostasis
CN119684441B (zh) 一种衍生多肽pm6及其在抗血栓中的应用
US20230285523A1 (en) Use of elafin in the treatment of covid-19
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
US7772371B2 (en) Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
WO2022224249A1 (en) Procoagulant peptides and use thereof
ADANIR et al. The Levels of Von Willebrand Factor in Adult Patients with Familial Mediterranean Fever and it is Relationship with Platelet Activation
US20170035863A1 (en) Compositions Comprising Variegin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090211